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The clinical management of rectal cancer and colon cancer differs due to increased local 
relapses in rectal cancer. However, the current molecular classification does not differen-
tiate rectal cancer and colon cancer as two different entities. In recent years, the impact 
of the specific immune microenvironment in cancer has attracted renewed interest and 
is currently recognized as one of the major determinants of clinical progression in a wide 
range of tumors. In colorectal cancer, the density of lymphocytic infiltration is associated 
with better overall survival. Due to the need for biomarkers of response to conventional 
treatment with chemoradiotherapy in rectal tumors, the immune status of rectal cancer 
emerges as a useful tool to improve the management of patients.
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inTRODUCTiOn
Worldwide, the incidence of colorectal cancer (CRC) has been increasing in recent years, and this 
type of cancer is now the third leading cause of death in both genders in USA (1).
Among all new diagnoses, rectal cancer represents a third of cases. The distinction between colon 
(CC) and rectal cancer (CR) is largely anatomical and clinical but the issue of whether they are two 
different entities or the same disease is still under debate. From an anatomical point of view, the colon 
and rectum are different tissues as the colon originates in the midgut and hindgut, while the rectum 
originates from the cloana. Thus, the colon epithelium consists of simple columnar epithelium 
whereas that of the rectum is a transition from single columnar epithelium to stratified squamous 
epithelium. Furthermore, the anatomic location and therefore, vascular drainage are also different.
From a clinical point of view, we can also consider CRC as composed of two differential entities. 
In CC, local relapse is rare, and the cure rate with radical surgery may be as high as 70–80% in initial 
stages of the disease (2). In RC, local relapse and distant metastases are equally frequent without 
treatment (3). Therefore, local treatment with radiotherapy (RT) plays an important role in the man-
agement of RC but not in CC. Recently, the neoadjuvant treatment of RT with/without chemotherapy 
(QT) and radical surgery with complete mesorectal excision has become the standard treatment 
for locally advanced RC. This type of treatment has demonstrated a high rate of local control, an 
improvement in disease-free survival (DFS) and a better tolerance than adjuvant treatment (4–6). 
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Thus, neoadjuvant or preoperative treatment has emerged as an 
attractive therapeutic strategy for the following reasons:
 (i) Initially unresectable tumors can be downsized.
 (ii) The reduction of tumor size translates into an increased rate 
of anal sphincter preservation.
 (iii) The administration of prior chemotherapy may be associ-
ated with a reduction in micrometastases.
 (iv) RT toxicity is decreased.
 (v) The patient maintains a good physical condition and thus 
treatment compliance is enhanced.
However, the toxicity of RT is substantial and is associated 
with considerable morbidity and mortality leading to serious 
sequelae. The most important of these is actinic colitis that causes 
chronic diarrhea and potentially intestinal obstruction. Others 
toxicities are anorectal dysfunction or sacral microfractures. All 
these outcomes seriously impair the quality of life of the patients 
with RC (7).
FACTORS PReDiCTinG ReSPOnSe TO 
TReATMenT in ReCTAL CAnCeR
The response to neoadjuvant treatment depends on different 
factors such as radiation dose, type of QT, time until surgery, 
tumor size, and presence of complete pathologic response (8, 
9). Complete response, defined as the absence of viable tumor, 
occurs in 10–30% of cases (8, 10). The prediction of the response 
to neoadjuvant treatment is not possible, but it is highly desirable 
for the following reasons:
 (i) RT is a long and expensive treatment that increases morbid-
ity after surgery.
 (ii) Alternative therapeutic approaches to avoid radical surgery 
can be followed in certain patient populations. For instance, 
local excisions or “wait-and-see” policies (surveillance 
without surgery) in patients with complete response to 
neoadjuvant treatment with RT-QT in RC has yielded high 
rates of patients alive at 5 years (11–13).
For these reasons, new predictive factors of response are 
a matter of intense research. The parameters of tumor size 
and lymph node involvement, used in tumor staging, are not 
able to predict response to neoadjuvant treatment (14). Thus, 
several studies have been conducted in order to determine 
molecular biomarkers of response to treatment. Molecules 
such as K-RAS, p53, the vascular endothelial growth factor 
(VEGF), the receptor for epidermal growth factor (EGFR), or 
proteins associated with apoptosis have shown inconsistent 
results. Elsaleh et al. analyzed p53 by immunohistochemistry 
(IHQ) in biopsies from patients with RC, but this parameter 
did not predict response to treatment with 45  Gy of RT and 
5-fluorouracil over 5  weeks (15). However, Garcia-Aguilar 
et  al. determined mutated K-RAS, p53, and polymorphisms 
of cyclin D1 (CCND1 G870A) and methylenetetrahydrofolate 
reductase (MTHFR C677T) in paraffin tissues of RC. The 
combination of these four molecular biomarkers is able to 
predict the response to treatment: patients harboring these 
mutations/polymorphism profiles will not achieve complete 
response (16). Other important mutations in CRC such as 
BRAF, β-catenin, or PIK3CA were not associated with response 
to neoadjuvant treatment.
Zlobec et  al. reported that low VEGF and high EGFR 
expression were associated with a high probability of achieving 
complete pathological response after a short course of RT and 
brachytherapy (17).
The development of genomic techniques allowed Ghadimi 
et  al. to analyze a gene expression signature that could predict 
response to treatments with QT-RT. These authors used 30 sam-
ples from the CAO/ARO/AIO-94 trial (4) and identified a gene 
profile that predicted response to treatment with a sensitivity of 
68% and a specificity of 78% (18). However, the authors included 
as responders patients with grade 3 or 4 tumor regression, and 
therefore further analyses are required. Others molecules such as 
survivin, bcl-2, bax, and COX2 have been explored, but no bio-
marker of response to neoadjuvant treatment in RC is at present 
widely accepted (19, 20).
MOLeCULAR CLASSiFiCATiOn OF CRC
Due to the anatomical and clinical differences between CC 
and CR and the need for a biomarker of response to treatment, 
many studies have attempted to divide CRC into two neoplasms 
based on molecular characteristics. Li et al. studied 230 patients 
with stage I–III CC or RC. The clinical and pathological char-
acteristics did not differ between patients, but CC had a better 
prognosis than RC (21). Azzoni et al. conducted a study in 120 
patients with stage I–IV CRC. They differentiated two groups: 
right tumors (proximal to the splenic flexure) and left tumors 
(distal to the splenic flexure) and studied the paraffin tissues 
obtained in the radical surgery of the tumors. They analyzed 
microsatellite instability (MSI), loss of heterozygosity (LOH), 
Fhit, p27, and COX2. These researchers concluded that right 
tumors were characterized by mucinous type, loss of expression 
of cyclin-dependent kinase inhibitor p27, presence of MSI, and 
low expression of Fhit. In contrast, left tumors were characterized 
by LOH. This group also determined whether there were differ-
ences in DFS and overall survival (OS) between the two types 
of tumors, but the results were not significant. However, in this 
study, the difference between the survival curve of patients who 
had MSI CRC and that of patients with LOH CRC was close to 
statistical significance, independently of the localization of the 
tumor (22). Recently, the Cancer Genome Atlas Network have 
conducted genome-scale analyses of 276 samples of CRC pairs 
with normal tissue (23). Their results established that CC and RC 
have remarkably similar patterns of genomic alterations (exclud-
ing hypermutated cancers). They observed that right tumors were 
most frequently methylated and they had high rate of mutations. 
Finally, an international consortium has proposed a CRC classi-
fication based on four consensus molecular subtypes (CMS). The 
first group, termed CMS1 (MSI immune) includes hypermutated 
tumors with high MSI and strong immune infiltration. The 
FiGURe 1 | Molecular biomarkers of right and left colorectal tumors. 
The recent consensus of CRC subtypes describe four types of CRC. The 
characteristics of CMS1 and CMS2 are very similar to the right and left 
tumors, respectively.
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second group (CMS2, canonical) comprises epithelial tumors 
with the strong involvement of WNT and MYC. CMS3 (meta-
bolic) is encompassed by tumors with a metabolic dysregulation 
and finally, CMS4 (mesenchymal) is made up of tumors with a 
strong TGFβ signature (24).
Therefore, this consensus classification did not provided a 
basis for a differentiation between colon and rectal cancer but 
the characteristics of CMS1 and CMS2 are very similar to the 
right and left tumors, respectively (Figure 1).
THe ROLe OF THe iMMUne SYSTeM in 
THe PROGReSSiOn OF COLOReCTAL 
CAnCeR
In recent years, the impact of the specific tumor microenviron-
ment in cancer has attracted renewed interest, and it is currently 
recognized as one of the major determinants of clinical progres-
sion in a wide range of tumors. In the tumorigenesis of CRC, 
genetic and epigenetic changes can lead to the production of 
abnormal proteins and derived peptides that are recognized as 
neo-antigens and can induce an adaptive immune response that 
effectively limit tumor growth and/or metastasis (25).
The survival advantage of a pronounced lymphocytic infiltra-
tion in different neoplasms has been well-known for many years 
(26) including in RC (27). The study of Pages et al. analyzed the 
immune response in 959 CRC tissue samples and the relation-
ship with pathologic signs of early metastatic invasion such as 
venus emboli and lymphatic and perineural invasion (28). In 
this study, the authors concluded that immune response in the 
tumor, characterized by the presence of CD3, CD45RO, and 
CD8 lymphocytes, was associated with the absence of histologic 
signs of early metastases. Moreover, the immune infiltration was 
associated with better OS. These researchers published another 
study where they analyzed the type, density, and location of 
immune cells within 415 CRC samples (29). They used IHQ 
techniques to analyze total T lymphocytes (CD3), CD8+ T cell 
effectors, and an effector cytotoxic molecule (GZMB), and a 
marker of memory T cells (CD45RO) in tumor two areas: the 
center of the tumor and the invasive margin (IM). The density of 
the immune infiltration in both areas was higher in patients with 
no relapse than in patients with tumor relapse. Higher density 
was also associated with better DFS and OS independently of 
the stage of disease, and therefore, the authors concluded that 
immune infiltration was a more valuable prognostic tool than 
TNM classification.
To further explore the complex interaction between CRC 
and the immune system, Galon and coworkers combined sev-
eral experimental approaches and visualization techniques to 
analyze the immune infiltration in 105 patients with CRC and 
the progression with tumor stage (30). Using genomic analysis, 
they analyzed 577 genes of the immune cells, and they discovered 
two clusters of patients. Cluster 1 was associated with patients 
with better DFS and was characterized by genes expressed in 
cytotoxic T cells, T helper cells, chemokine genes, and genes 
required for endothelial cell migration. The second cluster, with 
a worse clinical outcome, was characterized by genes involved 
in IL-2 signaling and in the regulation of the adaptive immune 
response. Using tissue microarrays, the authors examined the 
different immune cell subpopulations in the core of the tumor 
(CT) and in the IM. Most of the T cell subpopulation markers, 
CD3, CD8, CD57, CD45RO, and FOXP3 were highly expressed 
at early stages (T1) and decreased with tumor progression. In 
contrast, the density of B cells increased with tumor stage, as 
well as that of innate immune cells such as neutrophils and mast 
cells. At the tumor margin, the density of B cells was elevated 
and correlated with memory CD45RO+ T cells. The local coor-
dination shown in the T cell network underlines the existence 
of tumor-microenvironment compartments with different 
compositions that might influence the mobility and activity of T 
and B cells throughout tumor progression. This could be due to 
the local expression of CXCL13. Patients with CXCL13 deletion 
had a significantly higher risk of relapse that did patients without 
aberrations and also had a lower density of B cells and Tfh cells 
in the IM.
DiFFeRenCeS in iMMUne inFiLTRATiOn 
in ReCTAL AnD COLOn CAnCeR
All studies reported above analyzed CRC as the same neoplasm 
without distinguishing between CC or RC tissues. However, as we 
have reviewed above, these cancers present differences in clinical 
outcomes. Thus, some researchers have designed studies to inves-
tigate the difference in immune infiltration in CC and RC or have 
analyzed specifically the immune status of RC. Deschoolmeester 
et al. analyzed the immune infiltration in 215 cases of CC and 64 
tissues of RC. They performed immunohistochemical detection 
of CD3+ T lymphocytes, CD8+ T lymphocytes, and the effector 
molecule granzyme B. Lymphocytic infiltration correlated with 
OS in cases of CC but not in RC (31). In contrast, Nagtegaal et al. 
studied 1530 patients with RC and demonstrated that lympho-
cytic infiltration was associated with a lower risk of relapse. In 
particular, CD4 infiltration decreased the risk of local relapse 
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while CD8 and CD3 infiltration was related to a decrease in 
distant metastases (32).
Other component of the immune system may reflect evasion 
mechanisms such as T regulatory cells or classical human leu-
kocyte antigen (HLA). Tumor-associated antigens are presented 
through HLA to T cells. Loss of HLA decreases the exposure of 
tumor-associated antigens and therefore is a mechanism to avoid 
T cell-mediated tumor destruction (33). T regulatory cells are a 
type of immune cell that is accumulated in the tumor microen-
vironment, suppressing antitumor effector immune responses 
(34). A retrospective analysis of 495 untreated patients with RC 
showed that the loss of expression of HLA was found in advanced 
stages or with positive lymph node involvement. Intriguingly, 
tumors with normal HLA expression had higher T regulatory cell 
densities. It is likely that T regulatory cells in this case reflect an 
inflamed tumor infiltrated by several immune cell populations. 
Based on these data, the authors defined three groups. Phenotype 
3 was defined by lack of expression of HLA type I, weak expres-
sion of HLA-G, and low expression of FoxP3. This phenotype 3 
was associated with a worse DFS than the phenotype 1, defined 
by high expression of HLA class I, HLA-G and FoxP3 (35). In 
line with these results, McMullen et  al. analyzed the immune 
response in 60 lymph nodes associated with RC mucosa. In this 
study, they focused on the quantities of T cells and dendritic cells. 
They concluded that the infiltration of these immune cells was 
associated with better OS (36). Therefore, although in the study of 
Deschoolmeester et al., immune infiltration in rectal cancer was 
not associated with OS, the remaining studies found a significant 
association between immune status of rectal cancer and clinical 
response.
iMMUne inFiLTRATiOn AS A BiOMARKeR 
OF ReSPOnSe TO TReATMenT
Other studies have addressed the possibility of using immune 
infiltration and a biomarker to predict the response to treatment 
in RC. An early study performed by Szynglarewicz et al. analyzed 
55 patients with stage I–III RC who underwent surgery plus 
adjuvant QT-RT. The presence of lymphocytic infiltration was 
associated with recurrence-free survival only in univariate analy-
sis (37). More recently, Yasuda et al. analyzed the density of CD4+ 
and CD8+ T lymphocytes in RC before any neoadjuvant treatment 
in 48 patients. They demonstrated that the patients with better 
response to QT-RT neoadjuvant therapy had a greater density 
of lymphocytes (38). These results were corroborated by Pages 
et al. who analyzed the immunoscore in 55 tissues of RC before 
QT-RT treatment. The immunoscore analyzed the presence of T 
lymphocytes using the CD3 marker, CD8+ T lymphocytes using a 
TABLe 1 | Summary of studies that analyze immune infiltration in colorectal cancer.
Type of 
tumor
Reference number patients and 
stage
iHQ analysis Results
CRC (28) 959 (287 were RC). 
Dukes A–D
CD3, CD45RO, CD8 – Immune response higher in patients without signs of early 
metastases
– CD8 density higher in patients without relapse
– High level of CD45RO associated with early stage and  
better OS
CRC (29) 415 (stage I–IV) CD3, CD45RO, CD8 (center of tumor 
and invasive margin) “Inmunoscore”
– Density of immune cells higher in patients without relapse
– Density of immune cells associated with OS and DFS 
independently of TNM
CRC (31) 215 (64 were CR)  
(stage I–IV)
CD3 and CD8 – Infiltration of lymphocytes higher in MSI tumors
– Better prognosis for MSS tumor with CD8 infiltration
– Lymphocytic infiltration was associated with better OS in CC 
but not in RC
CRC 599 (stage I–IV) CD45RO, CD8 – Higher infiltration in early stages
– Better OS with low immunoscore
– Decrease of CD8 infiltration with worse T or N stage
– Decrease infiltration in patients who relapse independently 
of TNM
CRC (30) 105b CD3, CD8, CD57, and FOXP3 – Infiltration of immune cells in early stage and decrease in 
advanced disease.
CRC 141 cases MSI+b CD3, CD8, and FOXP3 – Increased CD8 infiltration when number of mutations is bigger
– Density of CD8 is not associated with OS
RC (27) 447 (Duke A–C) Lymphocytic infiltration – Decreased infiltration with advanced stage
– Higher infiltrations associated with better OS
RC (37) 55 (stage I–III) Lymphocytic infiltration – Presence of infiltrations associated with better OSa
RC (32) 1530 (stage I–IV) CD8, CD4, T cell, NK cells, 
macrophages
– Presence of infiltrations associated with low risk of relapse
– CD4 associated with reduced risk of local relapse
– CD8 and CD3 associated with distant metastases
CRC, colon and rectal cancer; CR, rectal cancer; OS, overall survival; DFS, disease-free survival; MSS, microsatellite stability; T, infiltration of the tumor; N, lymph node.
aOnly in univariate analysis.
bStage not described.
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